An exploratory study to investigate the pharmacokinetics and effects of DABIgatran etexilate in patients with stable severe RENAL disease: DabiRenal
Phase of Trial: Phase I/II
Latest Information Update: 16 Jan 2015
At a glance
- Drugs Dabigatran etexilate (Primary)
- Indications Deep vein thrombosis; Embolism; Pulmonary embolism; Stroke; Venous thromboembolism
- Focus Pharmacokinetics
- Acronyms DABIRENAL
- Sponsors Boehringer Ingelheim Pharmaceuticals
- 30 Jan 2014 Status changed from recruiting to completed, as per ClinicalTrials.gov record.
- 30 Oct 2013 Planned end date changed from 1 Nov 2013 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 22 Oct 2012 Planned End Date changed from 18 Apr 2013 to 1 Nov 2013 as reported by ClinicalTrials.gov.